Search

everythinglearnresearchcommunity

for

Search:↓

The guidelines suggest a detailed approach to diagnosing and treating lupus, with a focus on regular check-ups, personalized medicine, and a range of drug options for different cases.

Psychotropic medications can cause skin problems, including serious conditions, and patients should be monitored closely.

Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.

The document concludes that various dermatological treatments and drugs can cause skin reactions and side effects.

Researchers found a new mutation in the HR gene causing hair loss and skin bumps in a Pakistani family.

COVID-19 can cause skin issues like "COVID toes," rashes, hair loss, and hand eczema, and dermatologists are important for recognizing these signs.

Women with Systemic Lupus Erythematosus should have closely monitored pregnancies and avoid certain medications to improve their pregnancy outcomes.

An elderly woman with cancer improved after treatment for a rare skin condition with coiled hairs.

Get head MRI for babies with achondroplasia early, use free immunoglobulin light chains to detect certain neurodevelopmental disorders, and video calls work for speech therapy in patients with facial anomalies.

Patients with chronic skin conditions on systemic treatments did not have worse COVID-19 outcomes and could resume their treatments after recovery.

Preventive measures and effective management are crucial for reducing skin side effects in cancer treatment.

5% minoxidil foam once daily works as well as 2% minoxidil solution twice daily for female hair growth and is more convenient.

Natural products like propolis are causing more skin allergies, and certain skin treatments and medications have various side effects and risks.

Some patients taking antipsychotic medications experience skin reactions, ranging from mild to severe.

A patient developed a severe skin reaction and died after taking hydroxychloroquine for COVID-19.

Chemotherapy can cause various skin problems, and recognizing them helps improve patient care.

COVID-19 changed dermatology by increasing telemedicine and highlighting healthcare disparities.

COVID-19 patients often have skin issues like chilblain-like lesions and rashes, which can help in early diagnosis and sometimes indicate severe illness.

Some medications caused temporary health issues that improved after stopping the drugs, but two patients died from liver problems linked to carbamazepine.

Most HIV patients in the study showed skin and mucous membrane issues, with oral thrush being the most common.

Chemotherapy can cause skin issues and hair loss, and this guide explains how to manage them.

The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.

The document explains various skin conditions and their treatments.

The document concludes that Cutaneous Lupus Erythematosus has different forms, is influenced by genetic and environmental factors, and can be treated with various medications, but more targeted therapies are needed.

Many doctors lack knowledge about COVID-19 skin symptoms and need better education and guidelines.

Any drug can cause skin reactions, but antibiotics, NSAIDs, and psychotropic drugs are more common, with some reactions being life-threatening.

Shen-Min, a hair growth supplement, likely caused acute hepatitis in a woman, improving after she stopped taking it.

Long COVID causes a wide range of long-lasting symptoms that change over time and are hard to diagnose and treat.

TNF-alpha inhibitors can cause various immune-related skin issues.

The document concludes that better tools are needed to measure skin disease severity in dermatomyositis and cutaneous lupus erythematosus, and introduces the DSSI and CLASI as reliable instruments.